# Kimberly-Clark Corporation (KMB)

> Source: Nexqual · https://nexqual.com/KMB · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Kimberly-Clark Corporation (KMB), nexqual.com/KMB" · informational, not investment advice.

**Price:** USD 112.32 (+5.32% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 112.32 · day 107.41–112.39 · 52w 92.42–123.09 · market cap null · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $16.6B, net income $1.96B (11.8% margin), free cash flow $1.82B (SEC filings).
- 1 of 80 tracked superinvestors hold KMB (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 3 Form 4 filings, $690K; 3 not under a Rule 10b5-1 plan ($690K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Total return with dividends: 1Y -0.6% vs S&P 500 +14.9%; 5Y +2.6% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 1.63, revenue estimate $4.12B.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $19.4B | $20.2B | $17.1B | $16.8B | $16.4B | $16.6B |
| Gross profit | $5.99B | $6.22B | $6.27B | $6.29B | $5.92B | — |
| Operating income | $2.56B | $2.68B | $1.93B | $2.70B | $2.35B | $2.51B |
| Net income | $1.81B | $1.93B | $1.76B | $2.54B | $2.02B | $1.96B |
| EPS (diluted) | $5.35 | $5.72 | $5.21 | $7.55 | $6.07 | — |
| Free cash flow | $1.72B | $1.86B | $2.78B | $2.51B | $1.64B | $1.82B |
| Gross margin | 30.8% | 30.8% | 36.6% | 37.4% | 36.0% | — |
| Operating margin | 13.2% | 13.3% | 11.2% | 16.1% | 14.3% | 15.2% |
| Net margin | 9.3% | 9.6% | 10.3% | 15.1% | 12.3% | 11.8% |
| Revenue growth | +1.6% | +3.8% | -15.0% | -2.0% | -2.1% | — |
| Cash + short-term investments | $270M | $427M | $1.09B | $1.01B | $688M | — |
| Total debt | $8.57B | $8.42B | $7.98B | $7.42B | $7.17B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)

P/E at fiscal year-ends: Dec 2025 16.6x, Dec 2024 17.4x, Dec 2023 23.3x.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold KMB. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Mairs & Power | Mairs & Power Funds | 0.01% | $1.0M | Reduced -1.4% |

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 3 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-05-06 | Scribner Andrew | Controller, VP & FP&A | 4,095 | $401K | 100% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-04 | Chen Katy | President, Int'l Personal Care | 1,596 | $152K | 16% | No | Too little history (no open-market trades in 2023) |
| 2026-04-30 | Chen Katy | President, Int'l Personal Care | 1,405 | $136K | 17.8% | No | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-16 | BNP Paribas | Target raised | Neutral | $101 → $110 |
| 2026-10-13 | TD Cowen | Target lowered | Hold | $104 → $97 |
| 2026-10-05 | Wells Fargo | Target lowered | Equal-Weight | $105 → $100 |
| 2026-09-25 | B of A Securities | Target lowered | Buy | $122 → $120 |
| 2026-09-11 | Piper Sandler | Target lowered | Overweight | $121 → $118 |
| 2026-09-10 | Wells Fargo | Target lowered | Equal-Weight | $110 → $105 |
| 2026-08-05 | UBS | Target raised | Neutral | $115 → $116 |
| 2026-08-05 | TD Cowen | Target raised | Hold | $96 → $104 |
| 2026-07-21 | Barclays | Target raised | Equal-Weight | $101 → $115 |
| 2026-07-16 | UBS | Target raised | Neutral | $106 → $115 |
| 2026-07-08 | Wells Fargo | Target raised | Equal-Weight | $100 → $110 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | -0.6% | +2.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -0.6% | +0.5% |
| Volatility (annualized) | 29.4% | 21.0% |
| Max drawdown | -21.0% (Oct 2025→Apr 2026) | -30.8% (Mar 2025→May 2026) |

## Peers (Household & Personal Products)
KVUE (Kenvue Inc.) USD 19.88 +4.41% · EL (Estee Lauder Companies, Inc. (T) USD 107.72 +3.92% · CHD (Church & Dwight Company, Inc.) USD 108.86 +3.68% · CL (Colgate-Palmolive Company) USD 97.39 +4.27% · CLX (Clorox Company (The)) USD 88.66 +4.59% · UL (Unilever PLC) USD 67 +4.04%

## More
Full page: https://nexqual.com/KMB · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name KMB in their own reports (relationship from KMB's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | Suzano S.A. (SUZ) | 20-F 2026-03-24 | "In June 2025, we entered into an agreement with Kimberly-Clark Corporation ("K-C") for the acquisition of a 51% equity interest in a new company incorporated in the Netherlands (the "NewCo"), which wi…" |

## Revenue by business segment (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY | Operating income | Op. margin |
|---|---|---|---|---|---|
| NA | $2.70B | 64.4% | -1.2% | $725.0M | 26.9% |
| IPC | $1.49B | 35.6% | +4.0% | $186.0M | 12.5% |
| Corporate costs (not allocated) | — | — | — | -$278.0M | — |
| Total revenue | $4.19B | 100% | — | $633.0M | 15.1% |

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Baby and Child Care | $1.75B | 41.8% | -0.9% |
| Family Care | $1.01B | 24.2% | +1.8% |
| Adult Care | $493.0M | 11.8% | +0.2% |
| Professional | $476.0M | 11.4% | +2.4% |
| Feminine Care | $423.0M | 10.1% | +2.7% |
| All other | $30.0M | 0.7% | +3.4% |
| Total revenue | $4.19B | 100% | — |

## Customer concentration

Period ended 2025-12-31: 16% of revenue from unnamed direct customers (10-K, filed 2026-02-12).

## Company outlook (8-K filed 2026-10-15)

- "Consistent with Previous Expectations Final Third Quarter and Nine Months results to be Released November 5, 2026 DALLAS, October 15, 2026 – Kimberly-Clark Corporation (NASDAQ: KMB) (“Kimberly-Clark”), a core S&P 500 component, today provided estimated preliminary financial data for the three months ended September 30, 2026, on a Current Report on Form 8-K filed with the U.S."
- "Considering these preliminary results, Kimberly-Clark's outlook for 2026 remains consistent with previous expectations; specifically: · 2026 Organic Sales Growth to be approximately 100 basis points below its weighted average category growth in the categories and countries it competes."
- "In addition, this outlook excludes the impact of any potential acquisitions, including Kimberly-Clark's previously announced pending acquisition of Kenvue Inc."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $1.63 | $1.80 | -9.2% | $4.12B | 13 |
| Next quarter (ends 2026-12-31) | $1.65 | $1.75 | -5.5% | $4.13B | 14 |
| Current fiscal year (ends 2026-12-31) | $7.38 | $7.54 | -2.1% | $16.60B | 17 |
| Next fiscal year (ends 2027-12-31) | $7.41 | $7.56 | -2.0% | $17.03B | 15 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-06 (includes earnings 2026-11-05): ±5.3%; earnings reaction alone ±1.9%; last 8 reports averaged ±3.8%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-10-30 | 7 | 31.8% | ±3.8% |
| 2026-11-06 | 14 | 32.8% | ±5.3% |
| 2026-11-13 | 21 | 30.4% | ±6.0% |
| 2026-11-20 | 28 | 30.2% | ±6.7% |
| 2026-11-27 | 35 | 28.1% | ±7.1% |
| 2026-12-04 | 42 | 25.7% | ±7.5% |
| 2026-12-18 | 56 | 25.8% | ±8.5% |
| 2027-01-15 | 84 | 26.3% | ±10.2% |